CDK4 and liposarcoma: In clinical trials, NVP-HDM201 showed promising anti-leukaemic activity [63] in patients with wild-type TP53 (NCT02143635), and clinical safety and efficacy in combination with LEE011 (CDK4/6 inhibitor) were confirmed in patients with liposarcoma (NCT02343172) [64].